|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2020
12 months to Jun 30, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation, depletion and amortization | |||||
| Non-cash employee stock compensation expense | |||||
| Fair value changes in equity securities | |||||
| Loss on marketable securities | |||||
| Deferred tax (benefit) expense | |||||
| Impairment of royalty interests | |||||
| Other | |||||
| Changes in assets and liabilities: | |||||
| Royalty receivables | |||||
| Stream inventory | |||||
| Income tax receivable | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Income tax payable | |||||
| Mount Milligan deferred liability | |||||
| Other liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Sandstorm & Horizon acquisition, net of cash acquired | |||||
| Acquisition of stream and royalty interests | |||||
| Proceeds from the sale of the Versamet Shares and other securities | |||||
| Cash calls for Hod Maden equity method investment | |||||
| Proceeds from Khoemacau debt facility | |||||
| Proceeds from the sale of inventory - restricted | |||||
| Other | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Repayment of debt | |||||
| Borrowings from revolving credit facility | |||||
| Net payments from issuance of common stock | |||||
| Net proceeds from Sandstorm option exercises | |||||
| Horizon warrant payments | |||||
| Distributions to non-controlling interests | |||||
| Common stock dividends | |||||
| Other | |||||
| Net cash provided by (used in) financing activities | |||||
| Net increase (decrease) in cash and equivalents | |||||
| Cash and equivalents at beginning of period | |||||
| Cash and equivalents at end of period | |||||
Loading...